We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$119B
AUM Growth
-$2.4B
Cap. Flow
+$2.12B
Cap. Flow %
1.78%
Top 10 Hldgs %
24.78%
Holding
3,988
New
162
Increased
1,714
Reduced
1,756
Closed
200

Top Sells

Rank Stock Value
1
RTX icon
RTX Corp
RTX
+$99.6M
2
AAPL icon
Apple
AAPL
+$88.3M
3
MBB icon
iShares MBS ETF
MBB
+$85.4M
4
MTUM icon
iShares MSCI USA Momentum Factor ETF
MTUM
+$51.6M
5
CSCO icon
Cisco
CSCO
+$43.2M

Sector Composition

Rank Sector Weight
1 Technology 14.94%
2 Financials 8.89%
3 Healthcare 8.4%
4 Industrials 6.56%
5 Consumer Discretionary 5.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BTAI icon
3676
BioXcel Therapeutics
BTAI
$32.7M
$42.4K ﹤0.01%
1,049
-117
-10% -$11.8K
SCYX icon
3677
SCYNEXIS
SCYX
$48.3M
$42.2K ﹤0.01%
2,312
+150
+7% +$3.58K
MFV
3678
DELISTED
MFS SPECIAL VALUE TRUST
MFV
$42.1K ﹤0.01%
10,785
+99
+0.9% +$403
ETON icon
3679
Eton Pharmaceutcials
ETON
$1.17B
$41.7K ﹤0.01%
10,000
ICAD
3680
DELISTED
iCAD Inc
ICAD
$40.8K ﹤0.01%
19,350
-196
-1% -$467
PAVM icon
3681
PAVmed
PAVM
$32.9M
$40.6K ﹤0.01%
306
+233
+319% +$36.1K
CCLP
3682
DELISTED
CSI Compressco LP
CCLP
$40.3K ﹤0.01%
29,215
-42,485
-59% -$49.7K
B
3683
CALL
Barrick Mining
B
$67.7B
$39K ﹤0.01%
2,600
-32,000
-92% -$525K
TPIC
3684
DELISTED
TPI Composites
TPIC
$38.4K ﹤0.01%
14,487
-2,874
-17% -$17.6K
ME
3685
DELISTED
23andMe Holding Co
ME
$35.4K ﹤0.01%
1,809
+962
+114% +$27K
VMAR icon
3686
Vision Marine Technologies
VMAR
$3.81M
0
CGC
3687
Canopy Growth
CGC
$431M
$34.3K ﹤0.01%
4,375
-952
-18% -$5.82K
GRWG icon
3688
GrowGeneration
GRWG
$112M
$34.1K ﹤0.01%
11,664
-1,850
-14% -$6.07K
COMP icon
3689
Compass
COMP
$9.69B
$33K ﹤0.01%
11,370
-2,500
-18% -$8.84K
OPFI icon
3690
OppFi
OPFI
$588M
$32.1K ﹤0.01%
12,737
+1,000
+9% +$2.33K
DNN icon
3691
Denison Mines
DNN
$3.03B
$31.4K ﹤0.01%
19,030
+30
+0.2% +$42
SLQT icon
3692
SelectQuote
SLQT
$122M
$30.4K ﹤0.01%
26,000
ET icon
3693
PUT
Energy Transfer Partners
ET
$71.8B
$30K ﹤0.01%
2,500
CANO
3694
DELISTED
Cano Health, Inc.
CANO
$29.6K ﹤0.01%
1,166
+341
+41% +$28K
AMRN
3695
Amarin Corp
AMRN
$296M
$29.6K ﹤0.01%
1,607
-195
-11% -$4.23K
SATL icon
3696
Satellogic
SATL
$902M
$29K ﹤0.01%
+24,780
New +$41.7K
LCTX icon
3697
Lineage Cell Therapeutics
LCTX
$278M
$28K ﹤0.01%
23,769
DWTX
3698
Dogwood Therapeutics
DWTX
$67.3M
$27.7K ﹤0.01%
1,200
BCLI
3699
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$27.6K ﹤0.01%
9,191
-1,783
-16% -$40.5K
INVZ icon
3700
Innoviz Technologies
INVZ
$114M
$27.3K ﹤0.01%
14,000
+3,450
+33% +$9.27K

Similar funds

Raymond James & Associates's Q3 2023 Portfolio in Review

As of Q3 2023, Raymond James & Associates held 3,988 positions worth $119B, down 2% from $121B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q3 2023 filing shows 162 new, 1,714 increased, 1,756 reduced and 200 closed positions. Its largest new stake was InterContinental Hotels: 102,555 shares worth $7.67M. The largest sale was RTX Corp, an estimated $99.6M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2023 buy was InterContinental Hotels: 102,555 shares worth $7.67M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q3 2023, an estimated $630M increase.
  • Raymond James & Associates's biggest Q3 2023 reduction was RTX Corp, cutting an estimated $99.6M.
  • Raymond James & Associates fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $17.3M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $119B portfolio in Q3 2023.
  • Raymond James & Associates opened 162 new positions and closed 200 in Q3 2023.
  • Raymond James & Associates's portfolio value fell 2% quarter-over-quarter to $119B.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.